Common Contracts
3 similar Underwriting Agreement contracts by Allegheny Technologies Inc, Savient Pharmaceuticals Inc, Volcano Corp
CITIGROUP GLOBAL MARKETS INC. ALLEGHENY TECHNOLOGIES INCORPORATED Underwriting AgreementUnderwriting Agreement • May 19th, 2016 • Allegheny Technologies Inc • Steel pipe & tubes • New York
Allegheny Technologies Incorporated, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of $250,000,000 principal amount of its 4.75% Convertible Senior Notes due 2022 (the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to an additional $37,500,000 principal amount of its 4.75% Convertible Senior Notes due 2022 to cover over-allotments (the “Option Securities”, and together with the Underwritten Securities, the “Securities”). The Securities are convertible into shares (the “Underlying Shares”) of common stock, par value $0.10 per share (the “Common Stock”), of the Company at the conversion price set forth in the Prospectus (as defined below). The Securities are to be issued under a base indenture, dated as of June 1, 2009, (the “Base Indenture”) as suppl
VOLCANO CORPORATIONUnderwriting Agreement • December 5th, 2012 • Volcano Corp • Electromedical & electrotherapeutic apparatus • New York
Volcano Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities LLC and Goldman, Sachs & Co. and each of the other underwriters, if any, named on Schedule 1 hereto (each an “Underwriter” and collectively, the “Underwriters”), for whom J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as representatives (the “Representatives”), $400,000,000 principal amount of its 1.75% Convertible Senior Notes due 2017 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $60,000,000 principal amount of its 1.75% Convertible Senior Notes due 2017 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 1.75% Convertible Senior Notes due 2017 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and, if and to the extent issued, the Option Securities are herein referred to as the “Securities”. The Securities
SAVIENT PHARMACEUTICALS, INC. Underwriting AgreementUnderwriting Agreement • February 1st, 2011 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $200,000,000 principal amount of its 4.75% Convertible Senior Notes due 2018 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $30,000,000 principal amount of its 4.75% Convertible Senior Notes due 2018 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 4.75% Convertible Senior Notes due 2018 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Securities will be issued pursuant
